From the newsletter
South Africa-based pharmaceutical subsidiary Johnson & Johnson has recorded the fastest growth rate in terms of senior African staff among its peers in the past year. The company has boosted senior staff by 43%, or 799 new hires, according to LinkedIn data. It also leads with 30% expansion in sales and business development staff.
The growth spurt is likely due to Johnson & Johnson’s expanding investment in digital health infrastructure across Africa, including backing solar connectivity for rural hospitals. The initiative supports clinics in Uganda, Kenya, Nigeria, Rwanda, Malawi and Tanzania.
Pfizer follows Johnson & Johnson in senior staff growth at 26%, Bayer at 16%, Roche at 15%, AstraZeneca at 14%, Novartis at 12%, GSK at 11%, Sanofi at 7%, and both Novo Nordisk and Aspen Pharmacare at 1%.
More details
Pfizer forms a second tier of aggressive expansion after Johnson & Johnson, with workforce growth of 26% and sales and BD growth of 17%. The strong commercial hiring indicates a company actively pursuing market penetration and revenue growth. Pfizer appears to be expanding customer-facing and partnership functions alongside its broader workforce.
Bayer and Roche represent balanced growth stories. Bayer's 16% workforce increase paired with 11% sales and BD growth suggests a uniform expansion of both operational and commercial capabilities. Roche's 15% staff growth and 13% commercial growth are well aligned, indicating coordinated organisational scaling.
AstraZeneca and GSK appear to be strengthening internal capacity more than commercial reach. While AstraZeneca increased staff by 14%, sales and BD roles grew by only 5%. GSK shows a similar pattern, with 11% workforce growth but just 3% commercial expansion.
Novartis and Sanofi appear to be in measured expansion mode. Novartis recorded 12% workforce growth but only 5% growth in sales and BD staff, while Sanofi expanded its workforce by 7% with commercial hiring at 3%. These figures suggest continued investment in Africa but at a pace focused on strengthening existing operations rather than aggressively pursuing new markets.
Novo Nordisk and Aspen Pharmacare show signs of consolidation rather than expansion. Both recorded only 1% overall workforce growth, while Novo Nordisk actually reduced sales and business development headcount by 4% and Aspen remained flat.
Our take
The companies growing fastest in Africa are also hiring aggressively in sales and business development, signalling a race to strengthen market presence.
Pharmaceutical investment in Africa remains active, but the divergence in hiring rates suggests that some firms are pursuing expansion while others are prioritising efficiency of existing operations.